PRO: Procalcitonin has clinical utility in children with community-acquired pneumonia

Todd A. Florin; Derek J. Williams

doi:10.1093/jacamr/dlab158

PRO: Procalcitonin has clinical utility in children with community-acquired pneumonia

Todd A. Florin^*, Derek J. Williams

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Procalcitonin (PCT) is a useful, albeit imperfect, diagnostic aid that can help clinicians make more informed decisions around antibiotic use in children with lower respiratory tract infections (LRTI), including communityacquired pneumonia (CAP). Recent data suggest that a very low PCT concentration has a high negative predictive value to identify a population of children at low risk of typical bacterial infections. Although the preponderance of data on the clinical utility of PCT in LRTI come from adult studies, the potential for benefit is likely greatest in paediatric CAP and other LRTIs where viral aetiologies predominate, yet antibiotics are frequently prescribed.

Original language	English (US)
Article number	dlab158
Journal	JAC-Antimicrobial Resistance
Volume	3
Issue number	4
DOIs	https://doi.org/10.1093/jacamr/dlab158
State	Published - Dec 1 2021

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases
Immunology and Allergy
Microbiology
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jacamr/dlab158

Cite this

@article{27eb8b3bbb084ea8922ddd94907bfd8a,

title = "PRO: Procalcitonin has clinical utility in children with community-acquired pneumonia",

abstract = "Procalcitonin (PCT) is a useful, albeit imperfect, diagnostic aid that can help clinicians make more informed decisions around antibiotic use in children with lower respiratory tract infections (LRTI), including communityacquired pneumonia (CAP). Recent data suggest that a very low PCT concentration has a high negative predictive value to identify a population of children at low risk of typical bacterial infections. Although the preponderance of data on the clinical utility of PCT in LRTI come from adult studies, the potential for benefit is likely greatest in paediatric CAP and other LRTIs where viral aetiologies predominate, yet antibiotics are frequently prescribed.",

author = "Florin, {Todd A.} and Williams, {Derek J.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s). Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.",

year = "2021",

month = dec,

day = "1",

doi = "10.1093/jacamr/dlab158",

language = "English (US)",

volume = "3",

journal = "JAC-Antimicrobial Resistance",

issn = "2632-1823",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - PRO

T2 - Procalcitonin has clinical utility in children with community-acquired pneumonia

AU - Florin, Todd A.

AU - Williams, Derek J.

PY - 2021/12/1

Y1 - 2021/12/1

N2 - Procalcitonin (PCT) is a useful, albeit imperfect, diagnostic aid that can help clinicians make more informed decisions around antibiotic use in children with lower respiratory tract infections (LRTI), including communityacquired pneumonia (CAP). Recent data suggest that a very low PCT concentration has a high negative predictive value to identify a population of children at low risk of typical bacterial infections. Although the preponderance of data on the clinical utility of PCT in LRTI come from adult studies, the potential for benefit is likely greatest in paediatric CAP and other LRTIs where viral aetiologies predominate, yet antibiotics are frequently prescribed.

AB - Procalcitonin (PCT) is a useful, albeit imperfect, diagnostic aid that can help clinicians make more informed decisions around antibiotic use in children with lower respiratory tract infections (LRTI), including communityacquired pneumonia (CAP). Recent data suggest that a very low PCT concentration has a high negative predictive value to identify a population of children at low risk of typical bacterial infections. Although the preponderance of data on the clinical utility of PCT in LRTI come from adult studies, the potential for benefit is likely greatest in paediatric CAP and other LRTIs where viral aetiologies predominate, yet antibiotics are frequently prescribed.

UR - http://www.scopus.com/inward/record.url?scp=85125113322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125113322&partnerID=8YFLogxK

U2 - 10.1093/jacamr/dlab158

DO - 10.1093/jacamr/dlab158

M3 - Article

C2 - 36275888

AN - SCOPUS:85125113322

SN - 2632-1823

VL - 3

JO - JAC-Antimicrobial Resistance

JF - JAC-Antimicrobial Resistance

IS - 4

M1 - dlab158

ER -

PRO: Procalcitonin has clinical utility in children with community-acquired pneumonia

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this